Drug Profile
Copper gluconate/disulfiram - Cantex Pharmaceuticals
Alternative Names: CX 02; Dicopp; Disulfiram/copper gluconate - Cantex Pharmaceuticals; DSF-CuLatest Information Update: 24 Mar 2023
Price :
$50
*
At a glance
- Originator Cantex Pharmaceuticals
- Class Antineoplastics; Heavy metals; Small molecules
- Mechanism of Action Aldehyde dehydrogenase inhibitors; Cell death stimulants; Proteasome inhibitors; Reactive oxygen species stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Glioblastoma; Pancreatic cancer; Prostate cancer
- Phase I Multiple myeloma; Myelodysplastic syndromes
- No development reported Brain metastases; Triple negative breast cancer
Most Recent Events
- 06 Feb 2022 Cantex Pharmaceuticals terminates phase I trial in Multiple myeloma (Second-line therapy or greater) in USA (unspecified route) (NCT04521335)
- 01 Oct 2021 Phase-I clinical trials in Myelodysplastic syndromes in USA (PO) (Cantex Pharmaceuticals, September 2021)
- 20 Sep 2021 Cantex Pharmaceuticals has patent protection for copper gluconate/disulfiram (Cantex Pharmaceuticals pipeline, September 2021)